AUA 2020

Researchers estimated a low excess risk of prostate cancer death for favorable-risk patients undergoing active surveillance rather than surgery: 1.1% to 8.7% over 15 years.

Two-year prostate cancer survival rates only increased from 60% in 2004 to 63% in 2014.

In a study of men with bone metastases from metastatic castration-resistant prostate cancer, black men had no significantly greater risk of skeletal-related events than nonblack men.